Background: Dextromethorphan (DM) is a widely-used antitussive. DM's complex central nervous system (CNS) pharmacology became of interest when it was discovered to be neuroprotective due to its low-affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonism. Review Summary: Mounting preclinical evidence has proven that DM has important neuroprotective properties in various CNS injury models, including focal and global ischemia, seizure, and traumatic brain injury paradigms. Many of these protective actions seem functionally related to its inhibitory effects on glutamate-induced neurotoxicity via NMDA receptor antagonist, sigma-1 receptor agonist, and voltage-gated calcium channel antagonist actions. DM's protection of dopamine neurons in parkinsonian models may be due to inhibition of neurodegenerative inflammatory responses. Clinical findings are limited, with preliminary evidence indicating that DM protects against neuronal damage. Negative findings seem to relate to attainment of inadequate DM brain concentrations. Small studies have shown some promise for treatment of perioperative brain injury, amyotrophic lateral sclerosis, and symptoms of methotrexate neurotoxicity. DM safety/tolerability trials in stroke, neurosurgery, and amyotrophic lateral sclerosis patients demonstrated a favorable safety profile. DM's limited clinical benefit is proposed to be associated with its rapid metabolism to dextrorphan, which restricts its central bioavailability and therapeutic utility. Systemic concentrations of DM can be increased via coadministration of low-dose quinidine (Q), which reversibly inhibits its first-pass elimination. Potential drug interactions with DM/Q are discussed.
D extromethorphan (DM) is a nonopioid morphinan derivative that has been used extensively and safely as a nonprescription antitussive for about 50 years. DM has a surprisingly complex central nervous system (CNS) pharmacology and related neuroactive properties, which began to be elucidated and to attract the interest of neurologists in the 1980s. 1 It is now established that DM acts as a low-affinity uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, 1-4 a high affinity sigma-1 receptor agonist, 5, 6 and a voltage-gated calcium channel (VGCC) antagonist. 7, 8 DM has also been shown to decrease potassium-stimulated glutamate release, 9 possibly via a sigma receptor-related mechanism. 10 Sigma-1 receptor agonists modulate extracellular calcium influx, as well as intracellular calcium mobilization. 6 Other activities of DM seem to include weak serotonin reuptake inhibition 11, 12 through proposed high affinity binding to the serotonin transporter. 13 In vivo, DM is quickly O-demethylated to its primary metabolite, dextrorphan (DX), 14 which has a similar, but not identical, pharmacological profile, acting at many, but not all, of the same sites, and with different affinities or potencies. 2, 4, 7, 13, [15] [16] [17] Several of the pleiotropic effects of DM serve to inhibit excitatory responses to glutamate, particularly via NMDA receptors, and to block multiple major routes of calcium entry into neurons. 7, 8 Given the unifying excitotoxic hypothesis of neuronal degeneration and death, DM's NMDA receptor antagonist, calcium channel antagonist, and possibly sigma-1 receptor agonist properties point toward potential efficacy as a neuroprotective agent. Abnormally elevated concentrations of glutamate are hypothesized to cause excessive excitation at the NMDA-subtype of glutamate receptors, and the influx of calcium causing neuronal damage. 18 Considerable evidence supports roles for excitotoxicity in acute disorders such as stroke, epileptic seizures, traumatic brain and spinal cord injury, as well as in chronic, neurodegenerative disorders such as Alzheimer disease (AD), Parkinson disease (PD), Huntington chorea (HD), and amyotrophic lateral sclerosis (ALS). 19 By pharmacologically inhibiting the release and subsequent deleterious actions of glutamate, DM could serve to protect neurons in a variety of neurologic disease and injury states.
Neuroprotective effects of DM were first recognized by Choi, who demonstrated that the drug attenuated glutamateinduced neurotoxicity in neocortical cell cultures. 20 Since this pioneering study, an increasing body of evidence has proved that DM possesses significant neuroprotective properties in a variety of preclinical CNS injury models (Table 1) . 15 DM protects against seizure-and ischemia-induced brain damage, hypoxic and hypoglycemic neuronal injury, as well as traumatic brain and spinal cord injury (Table 1 ). DM's protective action in the plethora of in vitro and in vivo experiments is attributed to diverse mechanisms. DM has been shown to possess both anticonvulsant and neuroprotective properties, which seem functionally related to its inhibitory effects on glutamate-induced neurotoxicity. 41 Antagonism of the NMDA receptor/channel complex is implicated as the predominant mechanism, 15 but DM's action on sigma-1 receptors is also positively correlated with neuroprotective potency. 26 Notably, DM's dual blockade of voltage-gated and receptor-gated calcium channels is proposed to produce a potentially additive or synergistic therapeutic benefit. 4, 8 Another suggested neuroprotective mechanism of DM underlying the antagonism of pchloroamphetamine (PCA)-induced neurotoxicity is the inhibi-tion of serotonin (5-HT) uptake by this agent. 66 Finally, it has been recently proposed that DM's interference with the inflammatory responses associated with some neurodegenerative disorders such as PD and AD may be a novel mechanism by which DM protects dopamine neurons in PD models. 61, 62 The potential efficacy of DM as a neuroprotectant was also explored in a limited number of small clinical trials in patients with ALS and perioperative brain injury. Additional small studies assessed symptom improvement with DM in HD, PD, and after methotrexate (MTX) neurotoxicity. DM was not found to be neuroprotective in the ALS trials, although the doses employed would not be expected to confer neuroprotection. 68 -70 In contrast, the study of patients with perioperative brain injury showed significant reductions in electroencephalographic (EEG) sharp-wave activity, and reductions in ventricular enlargement and periventricular white matter lesions that did not reach significance in a small sample of patients. 71 Symptomatic improvement was not found with DM in 1 open-label trial with HD patients. 72 DM did significantly improve levodopa-associated dyskinesias and off-time. 73, 74 DM also ameliorated primary PD signs in 2 studies, 75, 76 although a third pilot investigation using lower doses did not corroborate the latter result. 77 Notably, DM completely resolved neurologic deficits associated with MTX neurotoxicity in all of 5 cases, but a larger trial is needed to confirm these preliminary findings. 78 To date, primarily safety/tolerability studies have been conducted in neurosurgery patients, 79 ALS patients, 80 patients at risk for brain ischemia, 81 or with a history of cerebral ischemia. 82 These safety trials demonstrate the feasibility of long-term and high-dose administration of DM to patients with conditions associated with glutamate excitotoxicity, although DM was associated with dose-related adverse events (AEs). 72, 80 Given the favorable safety profile of DM and possible preliminary indications of neuroprotective potential in perioperative brain injury, 71 further studies are warranted.
Several investigators suggested that the limited benefit seen with DM in clinical trials is associated with the rapid hepatic metabolism of DM to DX, which limits systemic drug concentrations and potential therapeutic utility. 14, 83, 84 Although difficult to extrapolate human dose requirements from animal data, it seems that DM doses higher than typically used for antitussive effects (60 -120 mg/d, oral), and those used in most previous neuroprotection trials, are required for neuroprotection. 68, 81, 85 However, in the trial with HD patients, plasma concentrations were undetectable in some patients after DM doses that were up to 8 times the maximum antitussive dose. 72 One method for increasing the central bioavailability of DM is to coadminister the specific and reversible CYP2D6 inhibitor, quinidine, to protect DM from extensive first-pass elimination via the cytochrome P4502D6 enzyme. 83 This approach serves to enhance the exposure to DM and limit the exposure to DX, which may itself be beneficial. Although this active metabolite is partially responsible for the neuroprotective effects in some models, 24, 31, 35 its action as a more potent phencyclidine (PCP)-like uncompetitive NMDA receptor antagonist is also associated with psychotomimetic disturbances. [85] [86] [87] Given the robust preclinical 
PRECLINICAL EVIDENCE OF NEUROPROTECTIVE PROPERTIES OF DM
An impressive preclinical body of evidence has proven that DM has significant neuroprotective properties in many in vitro and in vivo models of CNS injury (Table 1) , including epilepsy, cerebral ischemia, traumatic CNS injury, and neurodegenerative diseases. 15 Briefly, DM attenuated morphologic and chemical evidence of neuronal damage in glutamate toxicity models, 21, 26 as well as the loss of vulnerable hippocampal (CA1) neurons in seizure 29 and global ischemia models. 41 DM decreased cerebral infarct size, areas of severe neocortical ischemic damage, and cortical edema after ischemia and reperfusion. 33, 34, 43, 45 In in vitro hypoxia models, DM reduced neuronal loss and dysfunction, manifest in a decreased amplitude of the anoxic depolarization. 52, 54 DM has also attenuated in vitro morphologic and chemical evidence of acute glucose deprivation. 55 An effect on regional cerebral blood flow (rCBF) was suggested to contribute to the neuroprotective action of DM in transient focal ischemia, since DM attenuated the sharp, postischemic rise in rCBF during reperfusion in the ischemic core and improved delayed hypoperfusion. 39 A comparable attenuation of postischemic hypoperfusion was found with DM in incomplete global cerebral ischemia. 37 Furthermore, there was strong evidence of a correlated improvement in brain function, as DM facilitated recovery of the somatosensory evoked potential 39 and attenuated EEG dysfunction in these and other ischemia studies. 37, 43 This is consistent with findings of improved neurologic function in focal ischemia. 47, 49 Similarly, the reduction in hippocampal damage in global ischemia with DM seemed to be the basis of improvement in spatial learning and memory. 44 In brain and spinal cord injury models, DM reduced histologic and biochemical damage, 57,58 blocked traumatic spreading depression limiting the spread of traumatic injury, 59 and also improved the bioenergetic state. 56 DM prevented the in vivo neurodegeneration of nigral dopamine neurons caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 62 and methamphetamine 64 in models of PD via a proposed reduction in microglial activation. Anal- ogous in vitro studies showed that DM reduced glutamate toxicity of dopamine neurons, 60 as well as inflammation or microglial-mediated degeneration of dopamine neurons induced by lipopolysaccharide (LPS) and MPTP, even at very low concentrations of DM. 62, 63 Finally, DM protected against the 5-HT depleting effects of PCA in 2 studies, 65, 66 but failed to do so in a third study. 67 This large collection of work points to potential therapeutic utility of DM for the treatment of various neurologic disorders. DX, the main active metabolite of DM, was found to be neuroprotective in many of the same studies as DM, particularly glutamate/NMDA toxicity and ischemia models (Table 1) . 21, 35 This is to be expected considering that DX has a similar pharmacological profile, although DM is a more potent antagonist of VGCCs, 15 has a slightly greater affinity for sigma-1 receptors, 17, 88 and is a less potent uncompetitive antagonist at NMDA receptors. 15 For example, DM seemed to be a more potent neuroprotectant than DX in a kainic acid-induced seizure model, for which a sigma-1 receptor mechanism was implicated. 31 In vitro and in vivo neuroprotection with DM occurred in comparable concentration ranges. 21, 40 Generally, in vitro protective properties were evident at concentrations as low as 10 to 15 M, with almost complete protection obtainable at 100 M. 20, 28, 52, 55 Much lower DM concentrations (microand femtomolar) inhibited microglial activation and inflammatory damage to dopamine neurons, whereas, interestingly, nano-and picomolar quantities showed no protective effects. [61] [62] [63] In vivo neuroprotective dose ranges were typically 10 to 80 mg/kg administered via various routes (Table 1 ). In rabbits, DM concentrated 7-to 30-fold in brain versus plasma, and brain levels were highly correlated with plasma levels. 40 Plasma levels Ն500 ng/mL and brain levels Ն10,000 ng/g, or approximately 37 M, were neuroprotective.
Although a therapeutic time window for neuroprotection has not been determined for DM in humans, findings in preclinical ischemia models have provided some insight in this regard (Table 1 ). Up to 1 hour delayed treatment was found to be beneficial in models of transient focal ischemia, 35, 40 similar to other neuroprotective NMDA receptor antagonists. 89 However, continuous perfusion of DM up to 4 hours after ischemic insult was shown to be necessary for maximum efficacy against focal ischemic damage. 42 This finding, and the use of multiple dose treatment paradigms in focal ischemia models, 45, 49 also suggest a DM neuroprotective effect on delayed neuronal damage.
Proposed Protective Mechanisms of DM
DM has a complex CNS pharmacology yet to be fully elucidated, but includes binding with high-or low-affinity to various receptor sites, ion channels, and transporters, each important to its neuroprotective actions (Fig. 1) . 4, 5, 13, 15 DM's neuroprotective properties seem to be related to its antiexcitotoxic effects in many CNS injury models (Table 1) . Glutamate excitotoxicity via NMDA receptors is a common pathway producing neuronal death in ischemia, hypoxia, hypoglycemia, prolonged seizures, neurodegenerative diseases, and traumatic brain and spinal cord injury. 18, 19 Impaired brain energy metabolism followed by depolarization releases excess glutamate and impairs reuptake mechanisms. Consequent over-activation of NMDA receptors causes an influx of sodium chloride and water, resulting in acute neuronal swelling and injury. 18 NMDA receptor stimulation and VGCC activation lead to excessive calcium influx, which produces delayed necrosis or apoptosis. 18,90,91 DM's lowaffinity uncompetitive NMDA receptor antagonism, 1,2,15 VGCC antagonism, 4, 8 and high-affinity sigma-1 receptor agonist activity 2,5,6 could block this pathogenic cascade at various points (Fig. 1) . FIGURE 1. DM may exert its neuroprotective effects to inhibit glutamate neurotoxicity through multiple actions. Abnormally elevated concentrations of glutamate lead to toxic increases in cytosolic free calcium culminating in neuronal necrosis or apoptosis. DM can reduce presynaptic calciumdependent glutamate release, 9 possibly through its action as a VGCC antagonist. Another more speculative mechanism is VGCC inhibition via a putative sigma receptor-coupled mechanism activated by DM. Postsynaptic neuroprotection against excessive glutamate is mediated by DM's antagonism of both NMDA receptor-and VGCC-mediated calcium influx, leading to a potentially additive or synergistic neuroprotective benefit. 4, 8 Finally, sigma-1 receptors, localized intracellularly pre-and postsynaptically, are thought to modulate intracellular calcium mobilization. 6 DM's action as a sigma-1 receptor agonist may thus serve to buffer toxic calcium concentrations. DM also inhibits microglial activation 61, 62 and serotonin reuptake [11] [12] [13] (not shown here), 2 additional proposed mechanisms of neuroprotection (see text). AMPA indicates ␣-amino-3-hydroxy-5-methylisoxazole-4-propionic acid-type glutamate receptor; Ca 2ϩ , calcium; DM, dextromethorphan; ER, endoplasmic reticulum; GLU, glutamate; Na ϩ , sodium; NMDA, N-methyl-D-aspartate-type glutamate receptor; PCP, phencyclidine; SIGMA-1, sigma-1 receptor; VGCC, voltage-gated calcium channels; ᮎ, inhibitory effect.
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Over a decade ago, NMDA receptor antagonism was suggested to be the predominant mechanism underlying neuroprotective/anticonvulsant properties of DM. 15 This is supported by findings in glutamate toxicity models, particularly the demonstration that neuroprotective potency correlated with the rank order for competition against ͓ 3 H͔MK801 binding to the site within the NMDA-operated cation channel. 27 However, attempts to attribute neuroprotective activity of DM purely to NMDA receptor/channel antagonism are complicated by its relatively low-affinity for that complex, 1,2 as well as by inconsistent findings regarding its ability to prevent glutamate neurotoxicity. 25 Moreover, DM has been shown to have a broader spectrum of neuroprotective effects compared with other NMDA receptor/channel antagonists, 89 with a longer therapeutic time window in focal ischemia 42 and an ability to inhibit delayed neuronal death in global ischemia. 41 It is therefore apparent that mechanisms that may include but are not limited to NMDA receptor/channel antagonism contribute to DM's neuroprotective actions. 89 These other DM neuroprotective mechanisms may include the blockade of calcium entry into neurons via both NMDA receptor-operated channels 8 and VGCCs, 4, 7 which occurs at neuroprotective drug concentrations. It has been suggested that DM's unique ability to inhibit calcium influx via dual routes could afford additive or synergistic neuroprotective effects. 4, 8 Moreover, presynaptic VGCC antagonism may reduce calcium-dependent glutamate release. 9 Indeed, calcium channel antagonism and inhibition of glutamate release have been implicated as potential neuroprotective mechanisms in global ischemia and hypoxic injury models (Table 1) . 41, 48, 54 Additionally, DM improves CBF in focal and global ischemia, but not in the normal brain, in such a way that it is thought to contribute to its neuroprotective action (Table 1) . 37, 39 DM's effect on CBF may result from blockade of VGCCs located on cerebral blood vessels resulting in vasodilation. 45 However, the mechanism is not known, and it is possible that the alterations in CBF seen with DM may be secondary to its prevention of excitotoxicity. 39, 45 Sigma-1 receptor agonist action is considered to be another important neuroprotective mechanism of DM. 2 A sigma-1 receptor-related mechanism was implicated in kainic acid-induced seizure models 31, 32 and a traumatic brain injury model, 59 in which sigma-1 receptor antagonists reversed the protective effects of DM (Table 1) . DeCoster et al found a positive correlation between neuroprotective potency and sigma-1 site affinity in a glutamate toxicity model. 26 It must be kept in mind that the majority of sigma-1 ligands tested in this correlational study, including DM, also have a significant to moderate affinity for the NMDA/PCP site. 26 However, selective sigma ligands with negligible affinity for the NMDA receptor complex also have notable in vitro neuroprotective efficacy in hypoxia/hypoglycemia models, although being less efficient against glutamate/NMDA toxicity. 10, 92 Further, selective sigma receptor agonists reduced neuronal damage in some but not other in vivo models of cerebral ischemia. 10 The precise role and physical nature of sigma-1 receptors in the CNS remains unclear. Sigma-1 sites are enriched in neuronal plasma membranes, intracellular membrane organelles, and cytoplasm. 6 Neurosteroids are the best candidate endogenous ligands for sigma receptors. [93] [94] [95] [96] Sigma receptors regulate the release of neurotransmitters, 6, 97 and are thought to do so by modulating calcium influx and intracellular calcium mobilization, and by acting upon PKC pathways. 6, 95 It is hypothesized that selective sigma ligands mediate neuroprotection by indirectly inhibiting ischemicinduced presynaptic glutamate release. 10 The reduction of glutamate release by DM 9 may therefore relate to a sigmarelated inhibition of VGCC-dependent synaptic release. 10, 96 In addition, DM could be neuroprotective via a sigma action on a putative postsynaptic and/or presynaptic intracellular target protein implicated in intracellular calcium buffering. 6, 10, 26 Although an indirect modulation of NMDA receptor activity is also involved in the neuroprotective effects of certain selective sigma ligands, the neuroprotective effects of DM have rather been related to a direct antagonism of the NMDA receptor complex. 10, 26 Some neuroprotective action in several preclinical models (Table 1) , as well as side effects, may be attributable to DM's active metabolite DX. Protective effects of both DX and DM have been chiefly noted in glutamate toxicity 21, 27 as well as in vitro and in vivo ischemia models. 35, 52, 55 Although specific reported affinities for DM and DX at the site within the NMDA receptor-operated cation channel vary, it is generally agreed that DX has a distinctly greater affinity than DM, 2,98 and DX has been shown to be about 8 times more potent than DM as an uncompetitive NMDA receptor antagonist. 15 Although DX's greater affinity at the PCP receptor within the NMDA receptor-operated channel is implicated in greater neuroprotective effects of the agent compared with DM in some models, 27, 52, 55 DX is also associated with psychotomimetic disturbances. [85] [86] [87] In contrast to DX, DM is more effective at inhibiting calcium uptake in vitro due to a 3 times more potent blockade of voltage-gated calcium flux. 4, 7, 15 Both drugs bind sigma-1 receptors and have been shown do so with a similar high affinity, 2, 99 or with DM having a slightly greater (about 2 times) affinity than DX. 17, 88 Evidence suggests that DM binds the serotonin transporter with high-affinity, 13 which might also confer neuroprotection in some paradigms, 66 whereas DX does not. 100 There may also be other sites at which DM or DX act, and it is unclear if the parent compound and metabolite bind the exact same site within the NMDA receptor-channel complex. 101, 102 Such mechanistic differences could account for the differential neuroprotective efficacies of DM and DX in various CNS injury models. 27, 31 In any event, protective effects of DM clearly go beyond effects of DX. For instance, in a focal ischemia study, Steinberg et al suggested that DM's neuroprotective action was not mediated by DX, since DX plasma and brain levels were lower than neuroprotective levels of DX in the same model. 40 Furthermore, focal administration of DM into the brain in 1 transient cerebral ischemia study was neuroprotective. 43 This effect, and the in vitro neuroprotective properties of DM, are not likely related to biotransformation of DM to DX. 103, 104 DM analogs have also demonstrated protective 105 DM has also inhibited inflammatory responses that are associated with neurodegeneration in chronic diseases such as PD and AD. 106, 107 This novel mechanism is proposed to underlie DM's protection of dopamine neurons in both in vitro and in vivo PD models. 61, 62, 64 DM was found to inhibit the activation of microglia, and their production of reactive oxygen species. The agent reduced LPS-and MPTP-induced production of proinflammatory factors, especially superoxide free radicals. [61] [62] [63] A final protective mechanism of DM was implicated in a serotonergic neurotoxicity model. 66 DM was shown to protect against the 5-HT depleting effects of PCA. 65, 66 The agent attenuated long-term reduction of 5-HT and its metabolite 5-hydroxyindoleacetic acid (5-HIAA) in rat striatum and cortex. Since potent and selective sigma receptor ligands did not antagonize PCA-induced neurotoxicity, sigma receptors were not thought to play a significant role. 66 Although tentative, it is proposed that DM exerted its beneficial effects by inhibiting 5-HT uptake. 66 This conclusion is supported by the fact that acute administration of DM decreases the 5-HIAA/ 5-HT ratio in brain, an effect which is well known to occur with 5-HT uptake inhibitors. 11 Furthermore, DM is proposed to bind with high affinity to the brain serotonin transporter. 13 Finally, action as a weak serotonin reuptake inhibitor has been ascribed to DM, because of its involvement in serotonin toxicity reactions with monoamine oxidase inhibitors. 12, 13 
CLINICAL FINDINGS FOR DM
The potential safety and efficacy of DM as a neuroprotective agent have been examined in a limited number of small clinical trials. These have primarily assessed the safety/ tolerability of the agent in various patient populations with both acute and chronic neurologic disorders. Symptom improvement was demonstrated in some studies. Although almost none of the studies to date has been specifically designed to evaluate neuroprotection, 4 studies were designed to allow some inference about neuroprotection, and 2 of these found neuroprotective effects. 68, 71 Studies with negative findings did not use doses sufficient for neuroprotection.
The largest (N ϭ 181) dose-escalation safety and tolerance study of DM was conducted in neurosurgery patients undergoing intracranial surgery or endovascular procedures, associated with a high risk of cerebral ischemia. 79 Patients were given oral DM (0.8 -9.64 mg/kg), starting 12 hours before surgery and continuing up to 24 hours after surgery. Serum DM levels correlated highly with cerebrospinal fluid (CSF) and brain levels. DM concentrated in brain with levels being 68-fold higher than in serum, similar to findings in animals. 40, 108 The maximum DM levels attained were 1514 ng/mL in serum and 92,700 ng/g in brain. In 11 patients, brain and plasma levels of DM were comparable to levels that have been shown to be neuroprotective in animal models of cerebral ischemia (serum DM Ն500 ng/mL and brain DM Ն10,000 ng/g). Frequent AEs occurring at neuroprotective levels of DM included nystagmus, nausea and vomiting, distorted vision, feeling "drunk," ataxia, and dizziness. All symptoms, even at the highest levels, proved to be tolerable and reversible, and no patient suffered severe adverse reactions. A few other, smaller studies have examined the role of orally administered DM in patients with stroke (N ϭ 22 total; DM serum levels ranging from 0 -189 ng/mL), 81, 82 HD (N ϭ 11; DM serum levels ranging from 0 -280 ng/mL), 72 and ALS (N ϭ 13; despite high doses, DM steady-state plasma levels were detectable in only 1 of 7 patients, with a C max of 190 ng/mL). 80 These studies found tolerable AEs at a variety of doses, ranging from 120 to about 960 mg/d. Common side effects included dizziness, dysarthria, and ataxia at lower doses and hallucinations and fatigue at higher doses. The role of high-dose oral DM in patients with ALS was evaluated in a phase 1, open-label safety study (N ϭ 13). 80 Escalating doses to a maximum tolerable dose of 4.8 to 10 mg/kg/d were given, and patients were maintained on this dose for up to 6 months. The most common AEs were light-headedness, slurred speech, and fatigue. Side effects were usually tolerable, although they became dose limiting in most patients. Neuropsychological testing detected no evidence of cognitive dysfunction at high doses in these ALS patients, 80 which was consistent with findings in a randomized, placebo-controlled safety study of patients with a history of cerebral ischemia (N ϭ 12). 82 Overall, the safety trials demonstrate the viability of both long-term and high-dose administration of DM to patients with conditions associated with glutamate excitotoxicity. 80 Given rapid conversion of DM to DX, it may be that some AEs encountered with DM administration are actually related to DX.
It is noteworthy that the safety/tolerability of DX was also assessed in a dose-escalation study with acute ischemic stroke patients (N ϭ 67). 86 Patients were treated with an intravenous (IV) infusion of DX within 48 hours of onset of mild-to-moderate hemispheric stroke. There was no difference in neurologic outcome at 48 hours between the DX-and placebo-treated subjects, although the study was not designed to evaluate efficacy. Common transient, reversible, and generally mild to moderate AEs included nystagmus, nausea, vomiting, somnolence, hallucinations, and agitation. Reversible hypotension was seen with higher loading doses of 200 to 260 mg/h. More severe AEs such as apnea or deep stupor were observed in patients given the highest doses of DX. Lower doses (loading doses of 145-180 mg, maintenance infusions of 50 -70 mg/h) were better tolerated and rapidly produced potentially neuroprotective plasma concentrations of DX (maximum serum levels ranging from 750 to 1000 ng/mL). DX has been found to be almost 8 times more potent than DM as a NMDA receptor antagonist, 15 and to have a much greater affinity for the PCP site in the NMDA receptor complex. 2 As could be predicted, the doses tested were associated with well-defined pharmacological effects compatible with blockade of the NMDA receptor. 86 These findings are consistent with animal studies in which PCP-like effects were observed with DX but not DM, 85, 87 and in which DM seemed to have a better therapeutic index at cerebroprotective levels. 40 There is preliminary clinical evidence for a neuroprotective effect of DM. Pilot data from a small randomized, placebo-controlled study (N ϭ 13) of perioperative brain injury in children undergoing cardiac surgery with cardiopulmonary bypass suggest such an effect. 71 DM (oral, high-dose 36 -38 mg/kg/d, dosing started 24 hours before and ended 96 hours after surgery) reached putative therapeutic levels in plasma (maximal about 550 -1650 ng/mL) and CSF (285-939 ng/mL), and significantly decreased postoperative EEG sharp waves (P ϭ 0.02). There were also reduced rates of postoperative periventricular white matter lesions (0/6 DM vs. 2/7 placebo) and less pronounced third ventricle postoperative enlargement (diameter 0.112 cm DM vs. 0.256 cm placebo; P ϭ 0.06), but small sample sizes may have precluded statistical significance. AEs were not observed. Reduced EEG sharp-wave activity, ventricular enlargement, and the absence of new white matter hyperintense lesions in the DM group may be indications of a neuroprotective effect. 71 However, dissimilarities of treatment groups by chance precluded firm conclusions.
Although ALS studies have produced disappointing findings, subneuroprotectant doses were employed in these investigations. A randomized, double-blind, placebo-controlled trial with ALS patients (N ϭ 45) did not demonstrate an improvement in 12-month survival with a relatively low dose of DM (150 mg/d; about 2-3 mg/kg). 68 Although there was a significantly decreased rate of decline in lower extremity function scores in the DM group, baseline differences between the groups precluded firm conclusions. A second 1-year trial (N ϭ 49) showed no significant differences in rate of disease progression between DM-(1.5 mg/kg/d) and placebo-treated patients. 69 Finally, in a third ALS study (N ϭ 14) no clinical or neurophysiologic parameter (relative number of axons, and compound muscle action potentials) improvements were found with DM in a 12-week placebo-controlled, crossover study (150 mg/d), followed by an up to 6 months open trial (300 mg/d). 70 As noted above, preclinical studies have established that considerably higher doses (about 10 -75 mg/kg, oral) are required for neuroprotective effects (Table 1) .
Symptom improvement with DM has been observed in some, but not all studies. A retrospective chart review (N ϭ 5) evaluated DM (oral 1-2 mg/kg) for severe subacute MTX neurotoxicity. 78 This is a frequent complication of MTX therapy for malignant and inflammatory diseases, the multifactorial pathogenesis of which is thought to involve NMDA receptor activation. 78 Remarkably, DM given 1 to 2 weeks after a dose of MTX completely resolved neurologic symptoms, including dysarthria and hemiplegia, in all patients. It is possible that DM could prevent permanent neurotoxic lesions associated with MTX therapy, but this was not assessed. 78 Two small studies with PD patients (N ϭ 22 total) lasting a few weeks showed significant efficacy for symptom improvement at daily doses ranging between 180 and 360 mg. 75, 76 A third study of PD patients (N ϭ 21) failed to find symptomatic improvement, but found dose-limiting side effects at 180 mg/d. 77 None of these 3 PD investigations employed neuroprotective methodology. DM also significantly improved levodopa-associated motor complications in 2 small trials (N ϭ 24 total), although with a narrow therapeutic index. 73, 74 Interestingly, the researchers coadministered DM (mean dose 95-110 mg/d) with quinidine (100 mg BID) in these trials. In any case, these studies of levodoparelated dyskinesias and motor fluctuations, lasting a few weeks, did not specifically examine neuroprotection. The mentioned open-label trial with HD patients (N ϭ 11) also found no windows of symptomatic benefit after 4 to 8 weeks of treatment, despite the achievement of a moderately high median peak tolerated dose (410 mg/d). 72 The authors evaluated symptomatic rather than neuroprotective benefits. At maximum doses, performance declined on a variety of measures of HD (functional rating scales and quantitative examination scores), consistent with dose-related side effects. Oral doses of DM did not correlate with serum levels, which varied widely (0 -280 ng/mL) and were randomly distributed. Although symptomatic benefit was not found, the investigators concluded that further trials of DM as neuroprotective therapy in HD may be called for given the proven safety of DM in HD patients, its salutary effects in animal models of the disease, and the hypothesis that striatal neuronal death in HD is mediated by NMDA receptors. 72 Taken together, the favorable safety profile of DM, the strong preclinical evidence of neuroprotective effects (Table  1) , the initial positive findings in several clinical studies, and the failure to obtain suitable plasma drug levels in many patients warrant further trials using strategies that enhance the central bioavailability of DM and limit the accumulation of DX. 14, 83, 84 
ENHANCING CENTRAL BIOAVAILABILITY OF DM AS A NEUROPROTECTIVE STRATEGY
Preclinical studies have suggested that neuroprotective effects of DM are dependent on adequate drug concentrations in the blood reaching the brain. For example, a greater reduction in ischemic neuronal damage was observed with higher plasma levels of DM in a rabbit model of transient focal cerebral ischemia. 40 In this study, neuroprotective brain levels were greater than 10,000 ng/g. Similarly, other studies have shown a dose-dependent decrease in ischemic or seizure-induced neuronal damage, 29, 38, 46 although a clear relationship between DM dose and degree of brain protection was not always found. 33, 49 Preclinical studies in which neuroprotection was observed used oral DM doses of about 10 to 75 mg/kg, whereas clinical neuroprotection studies have usually employed lower doses. As in humans, a substantial effect of first-pass metabolism on DM bioavailability has been shown in animals, and route-specific effects on the disposition of DM and DX in the plasma and brain must be considered. 109 Several investigators have proposed that the limited benefit seen with DM as a neuroprotectant in clinical trials is
Dextromethorphan undergoes extensive hepatic
O-demethylation to its primary metabolite dextrorphan. 14, 83, 84 In most humans, DM undergoes extensive hepatic O-demethylation to its primary metabolite DX, which is catalyzed by the polymorphic cytochrome P450 2D6 (CYP2D6). Metabolism is so great that after a single oral dose of DM (30 mg), DM was not detectable or at the limits of detection in the plasma of extensive metabolizers (N ϭ 5), constituting the majority of the population. 110 Poor metabolizers of DM comprise Յ7% of the population. 111 DX is rapidly glucuronidated and cleared, whereas DM is not conjugated and concentrates in the brain. 14 79 whereas cardiac surgery patients were dosed starting 24 hours before until 96 hours after surgery. 71 Such dosing regimens are not practical over the long-term, and may not be as well tolerated by patients that are awake and not under intensive care unit conditions. 71, 79 Limited systemic delivery of DM could thus, at least in part, account for disappointing trial results. Along these lines, it should further be noted that with the exception of the Schmitt et al study of patients with perioperative brain injury, 71 the other clinical trials of sufficient duration to evaluate neuroprotection (all in ALS patients) used inadequate mg/kg/d doses based on the existing body of preclinical evidence. In animal in vivo studies, DM doses of 10 to 80 mg/kg (administered PO, IP, SC, or IV) were generally associated with neuroprotective efficacy (Table 1), with the exception of a single study that used lower IV doses. 49 In a rabbit focal ischemia model, a 20 mg/kg (IV) loading dose alone was not neuroprotective, unless given with a 10 mg/kg/h maintenance infusion. 42 The single clinical study wherein neuroprotective effects were observed used DM oral doses between 36 to 38 mg/kg/d (concentrations of about 550 -1650 ng/mL maximum in plasma and 285-939 ng/mL in CSF). 71 In the other 3 clinical neuroprotection trials, oral doses of only 1.5 to 6 mg/kg/d were employed, which are about 10-to 20-fold below known neuroprotective doses. 68 -70 Enhancing the central bioavailability of DM may increase its therapeutic potential as a neuroprotectant. 14 DM doses needed for neuroprotection are greater than antitussive doses, 81, 85 but due to the pronounced metabolism of DM, therapeutic concentrations are not easily achieved by simple dosage adjustment. 83 Various methods of enhancing DM bioavailability have been proposed. For example, since the brain concentration of DM is believed to be route dependent, parenteral administration (eg, IV) has been used to avoid the first-pass effect. Similarly, the nasal route has been shown to be a viable alternative in animals, with drug absorption following IV profiles. 112 Nevertheless, oral administration remains the most convenient, particularly for potential treatment of chronic neurologic disorders. The most promising strategy for increasing systemically available DM, therefore, seems to be the coadministration of the specific and reversible CYP2D6 inhibitor, quinidine (Q). 14, 83, 110 Q administration protects DM from metabolism after oral dosing, and can convert subjects with the extensive metabolizer to the poor metabolizer phenotype. This results in elevated and prolonged DM plasma profiles, increasing the drug's likelihood of reaching neuronal targets. 14 This approach also improves the predictability in DM plasma levels, as a strong linear relationship was observed between DM dose and plasma concentration, when Q was coadministered with increasing doses of DM. 83 Finally, inhibition of DM metabolism limits exposure to DX, 14 implicated in psychotomimetic reactions and abuse liability. 110 Importantly, the use of Q inhibit the rapid first-pass metabolism of DM allows the attainment of potential neuroprotective drug levels in the brain. Pope et al demonstrated that about 30 mg Q is the lowest dose needed to maximally suppress O-demethylation of DM. 14 This dose, 30 mg twice daily (BID) given with 60 mg BID DM, increased plasma levels of DM 25-fold. In this manner, coadministration of 30 mg of Q BID with DM in the 3 unsuccessful ALS neuroprotection trials could have readily transformed the inadequate DM doses into standard neuroprotective plasma concentrations. Pope et al further showed that 120 mg daily DM (60 mg BID) with quinidine (30 mg BID) resulted in steady state peak plasma levels of 192 Ϯ 45 ng/mL and an AUC 0 -12 of 1963 Ϯ 609 ng⅐h/mL. 14 Given the 68-fold concentration of DM in brain found in neurosurgery patients, 79 
an estimated
The most promising strategy for increasing systemically available dextromethorphan, therefore, seems to be the coadministration of the specific and reversible CYP2D6 inhibitor, quinidine.
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The Neurologist • Volume 13, Number 5, September 2007 brain concentration of 13,100 ng/g (about 48 M) is achievable. This corresponds to neuroprotective levels established in preclinical in vitro 21 and in vivo 40 studies. A reasonable concern is that the achievement of higher DM plasma concentrations, as well as the use of Q, may be associated with an increased occurrence of AEs, particularly in patients with neurologic disorders. Fortunately, clinical studies to date have shown the combination of DM and Q to be generally well tolerated, although the incidence of AEs did seem to relate to DM dose. 14 Safety evaluations in healthy subjects (total N ϭ 120) showed that daily doses of up to 120 mg DM plus 120 mg Q administered for 1 week, resulted in mostly mild to moderate AEs. 14 No difference was found between the extensive and poor metabolizer phenotypes. The most commonly reported AEs were headache, loose stool, light-headedness, dizziness, and nausea. No electrocardiographic abnormalities were observed. In particular, there was no clinically significant change in the QT c interval. This is important, because Q use has been associated with QT c prolongation and the occurrence of a torsade de pointes based arrhythmia. 113, 114 However, the low doses of Q required to maximally inhibit DM metabolism, and to reach potentially neuroprotective levels of DM, are about 10-to 30-fold below the 600 to 1600 mg daily doses routinely used to treat cardiac arrhythmias. 113 The mentioned studies by Pope et al 14 provided the rationale for the proprietary fixed combination product AVP-923 (30 mg DM and 30 mg Q; Zenvia) in development by Avanir Pharmaceuticals (San Diego, CA). Two phase 3 clinical trials testing AVP-923 for Involuntary Emotional Expression Disorder have also shown the DM and Q combination to be generally well tolerated. In these trials with ALS (N ϭ 140) 115 and multiple sclerosis (N ϭ 150) 116 patients, daily doses of 60 mg DM plus 60 mg Q (30 mg DM/30 mg Q BID) given for 1 and 3 months resulted in mean steady state plasma levels of about 100 and 115 ng/mL, respectively. As in healthy subjects, use of AVP-923 in these patients with neurodegenerative disorders, even over a prolonged period, resulted in mostly mild to moderate AEs. The AEs reported more frequently with AVP-923 than its components (DM and Q alone) or placebo were dizziness, nausea, and somnolence. No clinically significant changes were noted in the QT c interval.
The administration of Q with DM can also potentially inhibit the metabolism of other drugs that are metabolized by CYP2D6. Although Bertz and Granneman 117 found about one quarter of a sample of 315 commonly prescribed drugs to be metabolized by this P450 isoenzyme, many drugs use multiple metabolic pathways and, in some of these, 2D6 constitutes a minority pathway. The list of agents of clinical significance in the context of Q is provided in Table 2 . Caution is indicated when coprescribing substrates, and especially inhibitors, of 2D6. Although dexamethasone and rifampin act as inducers in vitro and could theoretically lower DM levels, there are no clinically significant 2D6 inducers, alleviating this concern.
Overall, the use of low-dose quinidine to increase DM bioavailability holds promise as a potential neuroprotective strategy. This approach allows the predictable attainment of neuroprotective levels of DM found in preclinical studies, and the DM/Q combination (eg, the fixed combination product AVP-923) has been shown to be well tolerated in clinical trials. It was suggested over a decade ago that inhibiting the metabolism of DM to its primary active metabolite DX is unnecessary, 80 since DX was thought to be the more potent uncompetitive NMDA receptor antagonist and protective agent. 21 However, there is a continuously growing body of evidence which now demonstrates that DM itself is neuroprotective via diverse mechanisms beyond uncompetitive NMDA receptor antagonism (Table 1 ). In some models of CNS injury, DM has a greater neuroprotective potency than 31 This methodology is therefore worthy of exploration in the neuroprotective arena.
GENERAL CONCLUSIONS AND RESEARCH AGENDA
A large body of preclinical (Table 1) 15 and limited, suggestive clinical evidence 71, 78 demonstrate that DM possesses important neuroprotective properties, particularly with regard to excitotoxicity. 41 DM is generally well tolerated in humans, and the use of high doses over prolonged periods has been shown to be feasible. 72, 80 The use of Q to inhibit the metabolism of DM allows the attainment of predictable and potentially neuroprotective systemic levels of DM. 14 This drug combination was well tolerated in large clinical trials. 14, 115, 116 Together these findings point to the prospective therapeutic utility of DM or the DM/Q combination (eg, AVP-923) 115, 116 for the treatment of various acute and chronic neurologic disorders. DM may prove to be useful in epilepsy, stroke, traumatic CNS injury, and other diseases where excitotoxic mechanism play a significant pathogenic role. 18, 19 DM has evidenced neuroprotective effects in preclinical in vivo models of focal and global ischemia 34, 41 and in vitro hypoxic and hypoglycemic injury, 52, 55 suggesting application to stroke, cardiac arrest, and neuro-or cardiacsurgical procedures associated with a high risk of cerebral ischemia. The small clinical trial showing possible neuroprotection in perioperative brain injury in children undergoing cardiac surgery with cardiopulmonary bypass provides hope in this regard. 71 There is also preclinical evidence of DM neuroprotection in brain and spinal cord injury models. 57, 58 Good results have been obtained with administration prophylactically or within 1 hour after ischemia onset, 35, 40 and with dosing 4 hours thereafter 42 (Table 1) .
Considerable evidence also supports roles for excitotoxicity in neurodegenerative diseases such as HD, ALS, PD, and AD. 19, 118, 119 Although the results of 3 small DM clinical studies in ALS were negative, 68 -70 1 of these nevertheless showed a reduced decline in lower extremity function with DM. 68 Furthermore, these studies used subneuroprotective doses. The use of DM-plus-Q should alleviate this problem in the future.
Furthermore, inflammatory mechanisms including microglial activation play a prominent role in PD, 106 AD, 107 and ALS 120 pathogenesis. In this regard, DM has demonstrated neuroprotection from inflammation-mediated degeneration of dopamine neurons in PD models both in vivo and in vitro, 61, 62, 64 possibly by low-dose inhibition of microglial production of reactive oxygen species. 62, 63 Moreover, DM has been shown to improve PD symptoms 75, 76 and levodopainduced motor complications. 73, 74 Potential neuroprotective properties of DM in other conditions involving neurodegenerative inflammatory processes, such as AD, also seem worthy of pursuit. Given the unique, pleiotropic mechanism of DM, its possible therapeutic applications have only begun to be explored.
